Global Vaccine for Non-infectious Meningitis Market Insights, Forecast to 2029

Publication ID:

PB504231564

Publication Date:

May 29, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Meningococcal conjugate vaccine听is used to prevent infection caused by meningococcal bacteria.
The global Vaccine for Non-infectious Meningitis market is projected to grow from US$ 1 million in 2023 to US$ 2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 12.0% during the forecast period.
The US & Canada market for Vaccine for Non-infectious Meningitis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Vaccine for Non-infectious Meningitis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Vaccine for Non-infectious Meningitis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of Vaccine for Non-infectious Meningitis include Serum Institute, Sanofi SA, Pfizer, Nuron Biotech and JN-International Medical, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes:
This report presents an overview of global market for Vaccine for Non-infectious Meningitis, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Vaccine for Non-infectious Meningitis, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Vaccine for Non-infectious Meningitis, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Vaccine for Non-infectious Meningitis sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Vaccine for Non-infectious Meningitis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Vaccine for Non-infectious Meningitis sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Serum Institute, Sanofi SA, Pfizer, Nuron Biotech and JN-International Medical, etc.
By Company
Serum Institute
Sanofi SA
Pfizer
Nuron Biotech
JN-International Medical
Segment by Type
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
Men B Vaccines
Segment by Application
Meningitis
Septicemia
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Vaccine for Non-infectious Meningitis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Vaccine for Non-infectious Meningitis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaccine for Non-infectious Meningitis sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 Vaccine for Non-infectious Meningitis Product Introduction
1.2 Market by Type
1.2.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Polysaccharide Vaccines
1.2.3 Conjugate Vaccines
1.2.4 Combination Vaccines
1.2.5 Men B Vaccines
1.3 Market by Application
1.3.1 Global Vaccine for Non-infectious Meningitis Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Meningitis
1.3.3 Septicemia
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Vaccine for Non-infectious Meningitis Sales Estimates and Forecasts 2018-2029
2.2 Global Vaccine for Non-infectious Meningitis Revenue by Region
2.2.1 Global Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Vaccine for Non-infectious Meningitis Revenue by Region (2018-2023)
2.2.3 Global Vaccine for Non-infectious Meningitis Revenue by Region (2024-2029)
2.2.4 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Region (2018-2029)
2.3 Global Vaccine for Non-infectious Meningitis Sales Estimates and Forecasts 2018-2029
2.4 Global Vaccine for Non-infectious Meningitis Sales by Region
2.4.1 Global Vaccine for Non-infectious Meningitis Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Vaccine for Non-infectious Meningitis Sales by Region (2018-2023)
2.4.3 Global Vaccine for Non-infectious Meningitis Sales by Region (2024-2029)
2.4.4 Global Vaccine for Non-infectious Meningitis Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Vaccine for Non-infectious Meningitis Sales by Manufacturers
3.1.1 Global Vaccine for Non-infectious Meningitis Sales by Manufacturers (2018-2023)
3.1.2 Global Vaccine for Non-infectious Meningitis Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaccine for Non-infectious Meningitis in 2022
3.2 Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers
3.2.1 Global Vaccine for Non-infectious Meningitis Revenue by Manufacturers (2018-2023)
3.2.2 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Vaccine for Non-infectious Meningitis Revenue in 2022
3.3 Global Key Players of Vaccine for Non-infectious Meningitis, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Vaccine for Non-infectious Meningitis Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaccine for Non-infectious Meningitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Product Offered and Application
3.8 Global Key Manufacturers of Vaccine for Non-infectious Meningitis, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vaccine for Non-infectious Meningitis Sales by Type
4.1.1 Global Vaccine for Non-infectious Meningitis Historical Sales by Type (2018-2023)
4.1.2 Global Vaccine for Non-infectious Meningitis Forecasted Sales by Type (2024-2029)
4.1.3 Global Vaccine for Non-infectious Meningitis Sales Market Share by Type (2018-2029)
4.2 Global Vaccine for Non-infectious Meningitis Revenue by Type
4.2.1 Global Vaccine for Non-infectious Meningitis Historical Revenue by Type (2018-2023)
4.2.2 Global Vaccine for Non-infectious Meningitis Forecasted Revenue by Type (2024-2029)
4.2.3 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Type (2018-2029)
4.3 Global Vaccine for Non-infectious Meningitis Price by Type
4.3.1 Global Vaccine for Non-infectious Meningitis Price by Type (2018-2023)
4.3.2 Global Vaccine for Non-infectious Meningitis Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Vaccine for Non-infectious Meningitis Sales by Application
5.1.1 Global Vaccine for Non-infectious Meningitis Historical Sales by Application (2018-2023)
5.1.2 Global Vaccine for Non-infectious Meningitis Forecasted Sales by Application (2024-2029)
5.1.3 Global Vaccine for Non-infectious Meningitis Sales Market Share by Application (2018-2029)
5.2 Global Vaccine for Non-infectious Meningitis Revenue by Application
5.2.1 Global Vaccine for Non-infectious Meningitis Historical Revenue by Application (2018-2023)
5.2.2 Global Vaccine for Non-infectious Meningitis Forecasted Revenue by Application (2024-2029)
5.2.3 Global Vaccine for Non-infectious Meningitis Revenue Market Share by Application (2018-2029)
5.3 Global Vaccine for Non-infectious Meningitis Price by Application
5.3.1 Global Vaccine for Non-infectious Meningitis Price by Application (2018-2023)
5.3.2 Global Vaccine for Non-infectious Meningitis Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Vaccine for Non-infectious Meningitis Market Size by Type
6.1.1 US & Canada Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
6.1.2 US & Canada Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
6.2 US & Canada Vaccine for Non-infectious Meningitis Market Size by Application
6.2.1 US & Canada Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
6.2.2 US & Canada Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
6.3 US & Canada Vaccine for Non-infectious Meningitis Market Size by Country
6.3.1 US & Canada Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Vaccine for Non-infectious Meningitis Sales by Country (2018-2029)
6.3.3 US & Canada Vaccine for Non-infectious Meningitis Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Vaccine for Non-infectious Meningitis Market Size by Type
7.1.1 Europe Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
7.1.2 Europe Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
7.2 Europe Vaccine for Non-infectious Meningitis Market Size by Application
7.2.1 Europe Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
7.2.2 Europe Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
7.3 Europe Vaccine for Non-infectious Meningitis Market Size by Country
7.3.1 Europe Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Vaccine for Non-infectious Meningitis Sales by Country (2018-2029)
7.3.3 Europe Vaccine for Non-infectious Meningitis Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Vaccine for Non-infectious Meningitis Market Size
8.1.1 China Vaccine for Non-infectious Meningitis Sales (2018-2029)
8.1.2 China Vaccine for Non-infectious Meningitis Revenue (2018-2029)
8.2 China Vaccine for Non-infectious Meningitis Market Size by Application
8.2.1 China Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
8.2.2 China Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Vaccine for Non-infectious Meningitis Market Size by Type
9.1.1 Asia Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
9.1.2 Asia Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
9.2 Asia Vaccine for Non-infectious Meningitis Market Size by Application
9.2.1 Asia Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
9.2.2 Asia Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
9.3 Asia Vaccine for Non-infectious Meningitis Sales by Region
9.3.1 Asia Vaccine for Non-infectious Meningitis Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Vaccine for Non-infectious Meningitis Revenue by Region (2018-2029)
9.3.3 Asia Vaccine for Non-infectious Meningitis Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Type
10.1.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Market Size by Application
10.2.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Country
10.3.1 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Vaccine for Non-infectious Meningitis Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Serum Institute
11.1.1 Serum Institute Company Information
11.1.2 Serum Institute Overview
11.1.3 Serum Institute Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Serum Institute Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Serum Institute Recent Developments
11.2 Sanofi SA
11.2.1 Sanofi SA Company Information
11.2.2 Sanofi SA Overview
11.2.3 Sanofi SA Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Sanofi SA Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi SA Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Pfizer Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Nuron Biotech
11.4.1 Nuron Biotech Company Information
11.4.2 Nuron Biotech Overview
11.4.3 Nuron Biotech Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Nuron Biotech Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Nuron Biotech Recent Developments
11.5 JN-International Medical
11.5.1 JN-International Medical Company Information
11.5.2 JN-International Medical Overview
11.5.3 JN-International Medical Vaccine for Non-infectious Meningitis Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 JN-International Medical Vaccine for Non-infectious Meningitis Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 JN-International Medical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vaccine for Non-infectious Meningitis Industry Chain Analysis
12.2 Vaccine for Non-infectious Meningitis Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccine for Non-infectious Meningitis Production Mode & Process
12.4 Vaccine for Non-infectious Meningitis Sales and Marketing
12.4.1 Vaccine for Non-infectious Meningitis Sales Channels
12.4.2 Vaccine for Non-infectious Meningitis Distributors
12.5 Vaccine for Non-infectious Meningitis Customers
13 Market Dynamics
13.1 Vaccine for Non-infectious Meningitis Industry Trends
13.2 Vaccine for Non-infectious Meningitis Market Drivers
13.3 Vaccine for Non-infectious Meningitis Market Challenges
13.4 Vaccine for Non-infectious Meningitis Market Restraints
14 Key Findings in The Global Vaccine for Non-infectious Meningitis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Serum Institute
Sanofi SA
Pfizer
Nuron Biotech
JN-International Medical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂